Disease relevance of Program Development

• Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report [1].
• Metabolic bone disease and total parenteral nutrition: a progress report [2].
• An open, multicenter trial of recombinant tissue plasminogen activator in acute stroke. A progress report. The rt-PA Acute Stroke Study Group [3].
• Long-term management of polycythemia vera with hydroxyurea: a progress report [4].
• This report summarizes results of the clinical development program evaluating zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) in the treatment of hypercalcemia of malignancy (HCM) [5].

Psychiatry related information on Program Development

• The NIDA Medications Development Program has had success in developing, with pharmaceutical partners, levomethadyl acetate, buprenorphine, and buprenorphine/naloxone for opiate dependence [6].
• Nicotinic acid in the treatment of schizophrenias. Canadian Mental Health Association collaborative study: progress report II [7].

High impact information on Program Development

• Several new papers report progress on the structure and function of Arp2/3 complex [8].
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone [9].
• Editorial retrospective. Meningococcal A and other polysaccharide vaccines. A five-year progress report [10].
• Dynamin and its partners: a progress report [11].
• INTERVENTIONS: After a formal primary PCI development program was completed at all sites, patients were randomly assigned to receive primary PCI (n = 225) or accelerated tissue plasminogen activator (bolus dose of 15 mg and an infusion of 0.75 mg/kg for 30 minutes followed by 0.5 mg/kg for 60 minutes; n = 226) [12].

Chemical compound and disease context of Program Development

• Diploma in Hospital Infection Control: a progress report [13].
• Nitrendipine in older patients with isolated systolic hypertension: second progress report on the SYST-EUR trial [14].
• A progress report on the New Zealand Multicentre Parkinson's disease trial. A comparison of low-dose treatment with bromocriptine or L-dopa [15].
• NIDA's effort to develop new pharmacotherapies as an adjunct to the treatment of opiate addiction has already led to the approval of LAAM and an NDA development program for buprenorphine [16].
• Studies on dapsone-resistant Mycobacterium leprae in leprosy patients of Gudiyatham Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Centre, Karigiri. 2. A progress report [17].

Biological context of Program Development

• Geriatrics program development at Bowman Gray School of Medicine of Wake Forest University [18].
• The preclinical pharmacokinetics (PK) and pharmacology of ibandronate have been extensively explored in a large preclinical development program involving various recommended animal models of human osteoporosis [19].
• Disruption of the development program of myosin gene expression has been reported in chicken muscular dystrophy [20].
• This is a progress report of an attempt to deconstruct the signaling network underlying cell cycle control in the mouse Y1 adrenocortical cell line, aiming to uncover ACTH growth regulatory pathways [21].
• In addition, a 1.5-kb fragment of the zebrafish hsp70 gene promoter is sufficient to direct expression of a gfp reporter gene to the lens, suggesting that the hsp70 gene is expressed as part of the normal lens development program [22].

Anatomical context of Program Development

• As part of a development program for controlled- and extended-release formulations of isosorbide-5-mononitrate (ISMN), the rate and extent of drug absorption was evaluated after site-specific delivery in the gastrointestinal (GI) tract [23].
• Engineering of the extracellular matrix: working toward neural stem cell programming and neurorestoration--concept and progress report [24].
• A progress report of the Marshall Islands nationwide thyroid study: an international cooperative scientific study [25].
• Pantographic records on TMJ dysfunction subjects treated with occlusal splints: a progress report [26].

Associations of Program Development with chemical compounds

• During the Phase I, II, and III clinical development program, temafloxacin has demonstrated an excellent safety profile, with reported overall rates of adverse events comparable to quinolone and nonquinolone reference agents [27].
• This paper describes results of a pooled analysis of four placebo-controlled studies included in the development program of the antidepressant nefazodone [28].
• The recent development program for this class of antimicrobials as antimalarials makes our proof of principle of improved efficacy of triazines (compared with the gold standard treatment, pyrimethamine) against T. gondii especially promising [29].
• Apart from slowing the development program by lowering the temperature to 15 degrees C and shortening the incubation time to 4 min, the essential step in the modification is the combined use of an EDTA and Tris-acetate buffer solution which stops the reduction of silver ions [30].
• The unique preclinical profile of amifostine serves as the basis for the clinical development program for this new broad-spectrum cytoprotective agent [31].

Gene context of Program Development

• Probing the structure of the mitochondrial channel, VDAC, by site-directed mutagenesis: a progress report [32].
• Celiac disease: a progress report [33].
• Here we report progress in the refinement of the PARK3 locus and sequence analysis of candidate genes within the region [34].
• Structure-function studies of aromatase and its inhibitors: a progress report [35].
• The National Large Bowel Cancer Project: a progress report [36].

Analytical, diagnostic and therapeutic context of Program Development

• A review of preclinical program development for evaluating injectable carriers for osteogenic factors [37].
• Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report [38].
• The role of the dietitian in parenteral nutrition support involves direct patient care, consultative services, education, program development, and research [39].
• The Adult Health and Development Program (AHDP) is an intergenerational, interdisciplinary health promotion and rehabilitation program in which nursing and other college students are paired with older adults to engage in activities to improve their health and well-being [40].
• The Oregon Center for Complementary and Alternative Medicine career development program: innovation in research training for complementary and alternative medicine [41].

References